RARS

RARS Full Name

arginyl-tRNA synthetase

RARS Introduction

Arginyl-tRNA Synthetase (RARS) is an essential and evolutionarily conserved aminoacyl-tRNA synthetase that serves as a core enzymatic regulator of cellular protein translation, proteostasis, and multifaceted cytoplasmic signaling in mammalian cells. Encoded by the RARS gene located on human chromosome 5q34, this ubiquitously expressed enzyme is abundantly present in all human tissues, especially in highly proliferative, metabolically active cells and protein-synthesis-intensive tissues such as muscle, liver, and neural tissues. As a key member of the class I tRNA synthetase family, RARS is primarily responsible for catalyzing the specific ligation of L-arginine to its cognate tRNA, ensuring accurate and efficient arginine incorporation during mRNA translation and maintaining translational fidelity in the cellular proteome. Beyond its canonical enzymatic function in protein synthesis, RARS exhibits diverse non-canonical roles in cell proliferation, immune regulation, oxidative stress response, and signal transduction. Accumulating translational research confirms that dysregulated RARS expression, enzymatic dysfunction, or abnormal subcellular localization is closely associated with developmental disorders, metabolic defects, inflammatory lesions, and tumor malignant progression, making RARS an indispensable housekeeping gene and a high-value clinical biomarker for multiple human diseases.

Figure 1. Schematic structure of RARS.

Pathophysiological and Clinical Significance of RARS
Genetic mutation, abnormal expression, or subcellular mislocalization of RARS is strongly correlated with a wide spectrum of human diseases, exhibiting critical clinical diagnostic and prognostic value. In genetic disorders, germline loss-of-function mutations in RARS are the primary cause of hypomyelinating leukodystrophy, a rare neurological disease characterized by impaired myelin formation, neurodegeneration, and developmental delay in children. In metabolic diseases, RARS dysfunction disrupts amino acid metabolism and protein synthesis balance, leading to cellular energy deficiency, endoplasmic reticulum stress, and tissue metabolic disorder. In human malignancies, RARS is frequently significantly upregulated in lung cancer, breast cancer, gastric cancer, and hepatocellular carcinoma. Elevated RARS expression accelerates tumor protein synthesis, sustains rapid cancer cell proliferation, and promotes tumor invasion, metastasis, and metabolic reprogramming. Clinically, high RARS expression levels are closely associated with advanced tumor staging, poor differentiation, and unfavorable patient survival rates, making RARS a reliable prognostic biomarker and a promising targeted therapeutic candidate for both genetic neurological diseases and human cancers.

Immune and Inflammatory Regulatory Roles of RARS
Beyond its classic translational functions, RARS serves as a vital modulator of immune homeostasis and inflammatory signal transduction in multiple human tissues. RARS dysregulation significantly affects immune cell activation, cytokine production, and inflammatory microenvironment formation. Under pathological stimulation, abnormal RARS expression triggers endoplasmic reticulum stress and proteostatic imbalance, which further activates NF-κB and MAPK pro-inflammatory signaling cascades, promoting excessive secretion of TNF-α, IL-6, and other pro-inflammatory mediators. This process enhances immune cell infiltration and amplifies tissue inflammatory damage in chronic inflammatory disorders and infectious injuries. In contrast, physiological RARS expression stabilizes immune cell proteostasis, limits unnecessary inflammatory activation, and maintains immune tolerance and tissue microenvironment balance. This dual regulatory capability enables RARS to bridge translational dysfunction with chronic inflammation, participating in the progression of multiple immune-related and inflammatory diseases.

Alternate Names for RARS

RARS; arginyl-tRNA synthetase; arginine--tRNA ligase, cytoplasmic; arginine tRNA ligase 1; cytoplasmic; DALRD1; arginine tRNA ligase 1, cytoplasmic; arginyl-tRNA synthetase, cytoplasmic; ArgRS; MGC8641;